Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed Paul Anderson to its scientific advisory board.

ActivX Biosciences Inc., of La Jolla, Calif., promoted David Campbell to senior vice president, chemical sciences.

Agensys Inc., of Santa Monica, Calif., appointed Stanislaw Mikulski vice president, clinical and medical affairs.

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., appointed Muthiah Manoharan vice president, drug discovery.

Angiotech Pharmaceuticals Inc., of Vancouver, B.C., added George Daniloff as general manager and vice president of research and development at the California facility and Ross Erickson as vice president, operations.

Ardais Corp., of Lexington, Mass., appointed Todd Golub to its scientific advisory board.

Atlas Ventures, of Boston, promoted Alexander Bruehl, Graham O'Keeffe and Timothy Wilson to senior principal, and Paul Pospisil to principal.

Biogen Inc., of Cambridge, Mass., elected Lawrence Best to its board.

California Healthcare Institute, of La Jolla, Calif., elected John Martin and Richard Murphy to its board.

Chiron Corp., of Emeryville, Calif., appointed Richard Fredericks to its board.

Chronogen Inc., of Montreal, named Maha Katabi executive director of business development.

Cytochroma Inc., of Markham, Ontario, appointed Michael Mays vice president and chief financial officer.

Discovery Laboratories Inc., of Doylestown, Pa., appointed Vincent Benn vice president, clinical operations.

EntreMed Inc., of Rockville, Md., appointed Dane Saglio chief financial officer.

EpiTan Ltd., of Melbourne, Australia, appointed Iain Kirkwood chief administrative officer.